CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Wilson disease pharmacotherapy coverage criteria

Defines medical necessity criteria and authorization requirements for pharmacologic treatment of Wilson's disease for members of Neighborhood Health Plan of Rhode Island, including initial and continuation therapy and a quantity limit for penicillamine.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyWilson disease pharmacotherapy coverage criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization for up to 6 months when initial or continuation criteria are met; document diagnosis and specialist prescribing/consultation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsauthorization period

>=2clinical features required

8/daypenicillamine limit

<20 mg/dLceruloplasmin criterion

Coverage Criteria for Wilson Disease Pharmacotherapy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial approval criteria: A. Patient has documented diagnosis of Wilson's disease, confirmed by genetic testing showing biallelic pathogenic ATP7B mutations OR confirmation of at least two of the following clinical features: (i) Presence of Kayser-Fleischer rings; (ii) Serum ceruloplasmin level < 20 mg/dL; (iii) Liver biopsy consistent with Wilson's disease (copper dry weight > 250 mcg/g); (iv) 24-hour urinary copper > 40 mcg/24 hours.

Prescribing requirement: B. Medication is prescribed by, or in consultation with, a gastroenterologist, hepatologist, or liver transplant physician.

Zinc therapy requirement: C. Patient has experienced inadequate response, intolerance, or contraindication to zinc therapy, or zinc would not be an appropriate therapy.

Prior authorization requires documentation of prior zinc therapy attempt or rationale for why zinc is inappropriate.

Continuation Therapy

Covered when ALL of the following are met for continuation therapy:

Continuation criteria: A. Patient continues to meet initial approval criteria (see Initial Therapy).

Response to therapy: B. Documentation of a positive response to treatment as indicated by improvement in neurologic condition or improved liver findings.

For continuation requests provide clinical documentation of response (e.g., neurologic improvement, liver function or biopsy findings).

Laboratory and Diagnostic Thresholds

inv-05: serum ceruloplasmin

Serum ceruloplasmin< 20 mg/dL

ContextOne of the diagnostic criteria for Wilson disease when genetic confirmation is absent

UseRequired as part of confirmation when at least two clinical features are needed

inv-06: liver copper dry weight

Liver copper (dry weight)> 250 mcg/g

ContextReported from liver biopsy and used as a diagnostic feature for Wilson disease

UseCounts as one clinical feature when genetic testing is not confirmatory

inv-07: 24-hour urinary copper

24-hour urinary copper> 40 mcg/24 hours

ContextMeasured over 24 hours and used as a diagnostic feature for Wilson disease

UseCounts as one clinical feature when genetic testing is not confirmatory

Authorization, Documentation, and Denial Risk

Prior Authorization

Authorization duration — up to 6 months

Prior authorization is required for treatment of Wilson's disease; when all initial or continuation criteria are met, approval may be granted for up to 6 months.

Step Therapy

Zinc therapy requirement

Before authorizing alternative pharmacologic therapy, document that the patient has had an inadequate response to, intolerance of, or a contraindication to zinc therapy, or that zinc would not be appropriate.

Documentation Required

Required documentation

Include records that confirm diagnosis and that support the prescribing decision: genetic test results or clinical diagnostic features, prescribing or consultation notes from the treating specialist, and for continuation requests evidence of clinical improvement.

Genetic testing showing biallelic pathogenic ATP7B mutations OR documentation of at least two clinical features (Kayser-Fleischer rings; serum ceruloplasmin < 20 mg/dL; liver biopsy copper > 250 mcg/g dry weight; 24-hour urinary copper > 40 mcg/24 hours).
Prescribing or consultation note from a gastroenterologist, hepatologist, or liver transplant physician.
For continuation: documentation of positive response (improved neurologic condition or improved liver findings).

Denial Risk

Potential denial triggers

Requests may be denied if documentation does not confirm the diagnosis per policy or lacks required specialist involvement or evidence regarding prior zinc therapy.

No documentation confirming diagnosis by genetics or at least two listed clinical features.
Missing prescribing or consultation documentation from a gastroenterologist, hepatologist, or liver transplant physician.
No evidence of inadequate response/intolerance/contraindication to zinc therapy when required for alternative treatment.
For continuation requests, absence of documentation showing clinical improvement.

Diagnostic Definition and Confirmation

inv-13: Diagnostic confirmation

Diagnostic confirmationBiallelic pathogenic ATP7B mutations OR at least two of: Kayser-Fleischer rings; serum ceruloplasmin < 20 mg/dL; liver biopsy copper > 250 mcg/g dry weight; 24-hour urinary copper > 40 mcg/24 hours.

Genetic testingBiallelic pathogenic ATP7B mutations constitute definitive confirmation

Clinical featuresAt least two of the listed clinical features are required if genetic confirmation is not available

Provider roleUsed to determine eligibility for a 6-month authorization for therapy

Background

Wilson disease is an inherited disorder of copper metabolism caused by pathogenic variants in the ATP7B gene that lead to accumulation of copper in the liver and other organs. Diagnostic features include neurologic and hepatic manifestations and may be confirmed by genetic testing showing biallelic pathogenic ATP7B mutations or by meeting at least two clinical criteria such as Kayser-Fleischer rings, serum ceruloplasmin < 20 mg/dL, hepatic copper > 250 mcg/g dry weight, or 24-hour urinary copper > 40 mcg/24 hours.